References

  1. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen. 1997; 4(4): 181-246. PubMed | Google Scholar

  2. Morris JK, De Vigan C, Mutton DE, Alberman E. Risk of a Down syndrome live birth in women 45 years of age and older. Prenat Diagn. 2005 Apr; 25(4): 275-8. PubMed | Google Scholar

  3. Aymé S. Apport des registres à la décision en santé publique: l'exemple de la trisomie 21. Rev Epidemiol Sante Publique. 1996; 44 Suppl 1: S82-9. PubMed | Google Scholar

  4. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ. 1992 Apr 4; 304(6831): 867-9. PubMed | Google Scholar

  5. Nicolaides KH, Snijders RJ, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn. 1998 May; 18(5): 519-23. PubMed | Google Scholar

  6. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988 Oct 8; 297(6653): 883-7. PubMed | Google Scholar

  7. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011 Jan;31(1):7-15. PubMed | Google Scholar

  8. Abid A, Abdelhedi F, Belguith N, Rekik H, Mallek S,Hamida N et al. Down's syndrome in Tunisia: incidence and spectrum of cardiovascular abnormalities. Cardiologie Tunisienne. 2013; 9: 154-6. PubMed | Google Scholar

  9. Watt HC, Wald NJ. Alternative methods of maternal weight adjustment in maternal serum screening for Down syndrome and neural tube defects. Prenat Diagn. 1998 Aug; 18(8): 842-5. PubMed | Google Scholar

  10. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med. 1999 Aug 12; 341(7): 461-7. PubMed | Google Scholar

  11. Audibert F, Dommergues M, Benattar C, Taieb J, Champagne C, Frydman R. Dépistage de la Trisomie 21: clarté nucale et/ou marqueurs sériques' Gynecol Obstet Fertil. 2001 Sep; 29(9): 599-604. PubMed | Google Scholar

  12. Thilaganathan B, Slack A, Wathen N. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol. 1997 Oct; 10(4): 261-4. PubMed | Google Scholar

  13. Kadir RA, Economides DL. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol. 1997 Apr; 9(4): 244-7. PubMed | Google Scholar

  14. Herman A, Maymon R, Dreazen E, Caspi E, Bukovsky I, Weinraub Z. Nuchal translucency audit: a novel image-scoring method. Ultrasound Obstet Gynecol. 1998 Dec; 12(6): 398-403. PubMed | Google Scholar

  15. Collège français d'échographie fœtale. Grille CFEF/CNRS. Paris: CFEF; 2006. Google Scholar

  16. Nicolaides KH. The 11-13+6 weeks scan. Fetal Medicine Foundation, London. 2004; 72-85. Google Scholar

  17. Axell RG, Gillett A, Pasupathy D, Chudleigh T, Brockelsby J, White PA et al. Accuracy of nuchal translucency measurement depends on the equipment used and its calibration. Ultrasound Obstet Gynecol. 2014 Jul; 44(1): 31-7. PubMed | Google Scholar

  18. Collège Francais d'Echographie Foetale. https://www.bionuqual.org/echo.php. consulté le 06 juillet 2013. Google Scholar

  19. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 1999 Apr; 13(4): 231-7. PubMed | Google Scholar

  20. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years prospective experience. BJOG. 2003 Mar; 110(3): 281-6. PubMed | Google Scholar